The Filing Desk

Champions Oncology vs Intellia Therapeutics

Champions Oncology CSBR · Intellia Therapeutics NTLA · Biotechnology

Intellia Therapeutics reported revenue of $68 million in fiscal 2025, about the same as Champions Oncology's $59 million in fiscal 2026. Champions Oncology's revenue grew 4.4% in its latest year, and Intellia Therapeutics' grew 16.9%. Champions Oncology had an operating margin of -1.9%, against -651.7% at Intellia Therapeutics. Free cash flow was −$5 million at Champions Oncology and −$396 million at Intellia Therapeutics. Their fiscal years end in different months (April 30 and December 31), so the periods don't line up exactly.

Side by side

Champions OncologyIntellia Therapeutics
Latest fiscal yearFY2026, Apr 30, 2026FY2025, Dec 31, 2025
Revenue$59M$68M
Revenue growth4.4%16.9%
Revenue growth a year, last 5 years7.7%3.1%
Gross margin48.0%—
Operating margin−1.9%−651.7%
Net margin−2.0%−609.9%
Free cash flow−$5M−$396M
Free cash flow margin−8.5%−585.0%
Return on capital——
Net debt to EBITDA——
Dividends and buybacks$0M$0M
Change in diluted share count−3.0%9.6%
Last close$4.40$9.52
P/E at the last close——
Insider trades, last 12 months—bought $1.4 million, sold $2.1 million
Piotroski F-score——
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
Champions OncologyIntellia Therapeutics
Operating margin
Percent of revenue
Champions OncologyIntellia Therapeutics
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Champions OncologyIntellia Therapeutics

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Champions Oncology and Intellia Therapeutics pages.